A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty

Phase 2

Completed

• Conditions: Subjects Requesting and Requiring an Open Rhinoplasty
• Interventions: Biological: ARTISS human fibrin sealant

• Registration Number: NCT01684020
• Lead Sponsor: DeNova Research

Brief Summary

Rhinoplasty (nasal reconstruction i.e. "a nose job") is a surgical procedure performed on the nose to correct a medical problem or change the appearance of the nose. During the healing process, swelling and/or bruising is likely to occur. A drug called ARTISS Fibrin Sealant may or may not lessen these effects. This study is looking to see the effects of ARTISS on adhering tissue and improving wound healing in an external rhinoplasty. The purpose of this study is to evaluate the safety and effectiveness of rhinoplasty using ARTISS compared to rhinoplasty without using ARTISS in patients undergoing rhinoplasty performed through an external approach.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-09-07
• Study First Submitted QC: 2012-09-10
• Study First Posted: 2012-09-12
• Study Start: 2012-11-28
• Primary Completion: 2016-04-26
• Study Completion: 2016-04-26
• Results First Submitted: 2020-08-11
• Results First Submitted QC: 2020-09-18
• Status Verified: 2020-10
• Last Update Submitted: 2020-10-12
• Results First Posted: 2020-10-14
• Last Update Posted: 2020-11-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Males and females between 18 and 65 years of age.

2. Subjects requesting primary rhinoplasty and requiring an external approach.

3. Subjects willing to undergo treatment with fibrin sealant.

4. Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.

5. Willingness and ability to comply with the PI's standard preoperative and postoperative rhinoplasty instructions.

6. Subjects of childbearing potential must have a negative urine pregnancy test result at Visit 1 and be willing able to use an acceptable method of birth control (e.g., barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following is documented on the medical history:

   • postmenopausal for at least 12 months prior to study drug administration
   • without a uterus and/or both ovaries
   • has had a bilateral tubal ligation for at least 6 months prior to study drug administration.
   • absence of an other physical condition according to the PI's discretion

7. Willingness and ability to provide written photo consent and adherence to photography procedures (i.e., removal of jewelry and makeup).

8. Willingness and ability to provide written informed consent prior to performance of any study related procedure.

Exclusion Criteria

1. Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control.
2. Subjects who are planning a concurrent facial surgery during the operation (eg forehead plasty, blepharoplasty, rhinoplasty, buccal fat removal, any filler injections including fat injections, lip augmentation, skin resurfacing procedures etc.).
3. Subjects with a previous history of rhinoplasty.
4. Subjects with a current history of smoking.
5. Subjects with a previous history of a bleeding or coagulation disorder .
6. Subject with a previous history of a vascular disorder, cardiovascular disease, and/or uncontrolled hypertension.
7. Subjects a previous history of diabetes mellitus with glycosylated hemoglobin (HbA1c) > 7.
8. Subjects undergoing active treatment for a malignancy.
9. Subjects with a previous history of has a connective tissue disorder.
10. Subjects with active or chronic skin disorder.
11. Subjects with a previous history of Bell's palsy.
12. Subjects with a previous history of pathologically or pharmacologically induced immune deficiency.
13. Subjects who have received chronic treatment with immunosuppressive drugs, systemic corticosteroids, or other chronic treatments within 30 days prior to the surgery.
14. Subjects with a known sensitivity to components of FS VH S/D 4 s-apr.
15. Subjects with a previous history of healing complications following previous surgeries (eg, hypertrophic scarring).
16. Subjects with a significant systemic illness or illness localized to the areas of treatment.
17. Subjects with previous history of nasal implants.
18. Subjects with previous or current history of nasal infections.
19. Subjects who have history of blood thinners (aspirin, ibuprofen, naprosyn, herbal supplements, Vitamin E) within the two weeks prior to surgery.
20. Subjects who have smoked within the two weeks prior to surgery.
21. Subjects who have had alcohol or illicit drugs one week prior to surgery.
22. Subjects who have eaten or drank anything after midnight the night prior to surgery.
23. Subjects with current history of chronic drug or alcohol abuse.
24. Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication.
25. Subjects who anticipate the need for surgery, other than the study procedure, or overnight hospitalization during the study.
26. Subjects who, in the Investigator's opinion, have a history of poor cooperation, non compliance with medical treatment or unreliability.
27. Subject has participated in another clinical study involving an investigational product/device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product/device during the course of this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ARTISS Human Fibrin Sealant	ARTISS human fibrin sealant	Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.

Primary Outcome Measures

Name	Time	Method
Edema Severity	Measured at Day 1, 7, 30, 180	Measured at Day 1, 7, 30, 180; 0 None- No apparent edema; 1. Mild- Minimal tissue swelling; 2. Moderate- Moderate edema, nasal features still discernible; 3. Severe- Marked swelling, difficulty distinguishing nasal features; Scores closer to 0 indicate more favorable results
Median Number of Adverse Events	1 day, 1 week, 4 weeks and 6 months following surgery	Safety will be assessed by the incidence of AEs throughout the study period as documented by clinician observations at study visits and in a 30-day subject diary.

Secondary Outcome Measures

Name	Time	Method
Ease of Use	Immediately Post Surgery	Ease of use will be determined by the treating investigator using a 10 cm Visual Analog Scale (VAS) to demonstrate technical ease.; (10) - Very diffiucult - (100) - Very easy; Scores closer to 100 indicate a more favorable outcome
Objective Ecchymosis Evaluation - PI	6 months	The surface area and color of ecchymosis will be evaluated at 1 day, 1 week, 4 weeks, and 6 months following surgery.; Rating Extent Color 0 No ecchymosis No color change; 1. Up to medial one-third of the lower and/or up eyelid Yellowish color change; 2. Medial half of the upper and/or lower eyelid Light purple; 3. Entire upper and/or lower eyelid Dark purple; 4. Entire part of the lower and upper eyelid and/or conjunctiva Very dark purple; 5. Extension of ecchymosis below the malar bone; Scores closer to 0 indicate a more favorable outcome.
Subject Downtime Questionnaire	1 day, 1 week, 4 weeks and 6 months following surgery	Subject downtime will be determined using a questionnaire at 1 day, 1 week, 4 weeks, and 6 months following surgery.; Responders are defined as those subjects experiencing little to no downtime.; Downtime scale: (3) Very Much (2) A Lot; (1) A Little (0) Not at all; Scores closer to 0 indicate more favorable outcome
Blinded-assessment of Satisfaction	Measured at Baseline, 1 month, 3 months, 6 months, 12 months	A non-treating blinded evaluator will assess satisfaction with a four-point categorical satisfaction scale \[unsatisfied (4), satisfied (3), very satisfied (2), highly satisfied (1))\] of subject's grafts using photographs from baseline, 1 month, 3 months, 6 months, and 12 months and will consist of a blinded evaluation in which the physician is aware of the type of graft, but unaware of plating status or the specific grafting site.; Scores closer to 1 indicate a more favorable outcome
Number of Participants With Adverse Events	Day 30	Subjects will complete a 30-day diary documenting adverse events such as erythema, pain, tenderness, firmness, swelling, lumps/bumps, bruising, itching and numbness.
Subjective Ecchymosis Evaluation - Subject	6 months	Ecchymosis will be determined by a live assessment at 1 day, 1 week, 4 weeks and 6 months following surgery using a six-point categorical edema scale.; Rating Extent Color 0 No ecchymosis No color change; 1. Up to medial one-third of the lower and/or up eyelid Yellowish color change; 2. Medial half of the upper and/or lower eyelid Light purple; 3. Entire upper and/or lower eyelid Dark purple; 4. Entire part of the lower and upper eyelid and/or conjunctiva Very dark purple; 5. Extension of ecchymosis below the malar bone
HPSS Assessment	1 week, 4 weeks and 6 months following surgery	Changes in subject self-esteem will be determined by subject completion of the Heatherton \& Polivy State Self-Esteem (HPSS) Scale at 1 week, 4 weeks and 6 months following surgery.; HPSS: scored between 1-5 for 20 questions with a total possible score between 20-100; 1. - Not at all; 2. - A little bit; 3. - Somewhat; 4. - Very much; 5. - Extremely; Scores closer to 100 indicate a more favorable outcome

Trial Locations

Locations (1)

DeNova Research; 🇺🇸 Chicago, Illinois, United States